India’s nutraceutical industry enters 2026 at a decisive stage in its evolution. It has grown at a phenomenal pace during the last decade. The factors contributing to this expansion include not only the rise in health awareness but also the availability of mass variety of nutra products. A niche market for health products has grown into a massive, globally interlocked industry, which has culminated in the transition from curative to preventive health focused consumers.
Yet this rapid expansion has also exposed a fundamental imbalance. India has built scale faster than systems. Manufacturing capacity has surged, product launches have multiplied, but the institutional architecture required to support credibility, consistency, and global competitiveness has lagged behind. Growth has outpaced structure—and it is this gap that now needs urgent correction.
The Indian nutraceutical market already crossed USD 30 billion in 2024 and is set to further expand by a CAGR of 13.6 per cent till 2030. The market is no more restricted to metropolitan cities; rural cities and towns are also accumulating steady market shares since consumers have begun investing in their own health at a younger age instead of seeking treatments at a ripe old age. This trend is not cyclic but structural and it is here to stay.
Globally, the opportunity is far larger. The global nutraceutical market is estimated at USD 500 billion, and demand for plant-based, functional, and personalised nutrition is accelerating. Despite India’s manufacturing base and botanical depth, its share in the global market remains limited. The constraint is not capability or demand. It is institutional readiness across regulation, validation, and quality systems.
Policy has begun to acknowledge this gap. The reduction of GST from 18% to 5% and the inclusion of nutraceuticals under the PLI framework signal intent. However, current incentives still favors capacity expansion over capability creation. For a sector built on science and consumer trust, this imbalance is consequential. Scale alone will not deliver global leadership.
To become globally competitive, we need to change the focus of the incentives programs and reward outcomes instead of just output. Further, clinical validation, generating intellectual property, exportability, and meeting international standards of quality could become as important as the output figures. For India, scale without credibility may generate numbers, but it will not build leadership.
Additionally, regulation is another area where course correction is urgently needed. Ongoing ambiguity over whether certain dietary supplements, particularly high-dose vitamins, minerals, amino acids, and botanicals, are classified as foods or drugs continues to impede progress. This uncertainty neither protects consumers nor enables manufacturers, who must navigate overlapping interpretations and approvals. A single, clearly defined regulatory authority is essential.
Quality should also be moved from the margins to center-stage. With increasing exports, worldwide purchasers are now focusing on the standards of testing and traceability, and so do the consumers expect at home. While standards do exist, the differing levels of enforcement and laboratory standards are causing doubts.
Raising credibility will not come from lowering expectations, but from standardising them. Systematic testing on a batch basis, aligned laboratory standards, and firm measures against sub-standard imported products are needed. India should compete on quality instead of compromising on the price .
There are also some concerns that reach up into the supply chain. A sector that relies on botanicals cannot afford any kind of uncertainty when it comes to traceability and sustainability. If there cannot be an ability to distinguish and trace different sources as either cultivated or harvested from the wild in an unambiguous and digitally traceable manner, India faces potential turbulence in the market.
Talent is another quiet constraint. Nutraceuticals sit at the intersection of food science, pharmacology, biotechnology, regulatory affairs, and supply chain management. While India produces a large number of science graduates, there is a shortage of professionals trained specifically for this sector. This gap will not be bridged by generic skilling schemes. It requires industry-led solutions, targeted certification programmes, industry-academia partnerships, and shared training platforms.
The urgency of these reforms is heightened by shifting trade dynamics. Uncertainty around tariffs in key export markets has reintroduced risk into what has been a critical growth engine. India’s push to accelerate Free Trade Agreements is a logical response, but liberalisation must be approached with care. FTAs open markets both ways, exposing domestic players to competitors with more mature ecosystems and deeper clinical infrastructure.
The answer is calibrated openness. Trade policy must be complemented by strong quality and traceability norms for imports, phased tariff adjustments, and time-bound safeguards where domestic capabilities are still evolving. Liberalisation should reward efficiency and quality not arbitrage.
Ultimately, this transition cannot be driven by government alone. Policy can set direction, but execution must come from industry leadership. Manufacturers, exporters, and associations must take ownership of building shared clinical research platforms, common quality benchmarks, pooled traceability systems, and sector-wide skilling initiatives. Waiting for regulation to impose discipline will only slow the sector’s progress.
2026 is not an ordinary growth year—it is the year India institutionalises its position as the world’s wellness capital. India can be at the forefront of this personalised nutrition revolution while maintaining its respected tradition of wellness that spans 5,000 years provided it has regulatory clarity, quality controls, talent, validation of clinical evidence, a strong supply chain, and a proper trade agenda.
The mathematics are compelling: USD 30 billion today, USD 100 billion by 2047. That aspiration is not hyperbole. It is achievable—provided policy, science, strategy, and industry leadership converge.
The moment is here.
The responsibility is shared.
And the choice is ours.
